Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-13
DOI
10.1038/s41467-020-20469-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity
- (2020) Mubeen M. Mosaheb et al. Nature Communications
- Tumor mutational burden is associated with poor outcomes in diffuse glioma
- (2020) Lihong Wang et al. BMC CANCER
- Mechanisms and therapeutic implications of hypermutation in gliomas
- (2020) Mehdi Touat et al. NATURE
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Longitudinal molecular trajectories of diffuse glioma in adults
- (2019) Floris P. Barthel et al. NATURE
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
- (2018) Frederick F. Lang et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- (2018) Marcin Kowanetz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
- (2017) Anna C. Filley et al. Oncotarget
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Spatiotemporal Evolution of the Primary Glioblastoma Genome
- (2015) Jinkuk Kim et al. CANCER CELL
- Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
- (2015) Hoon Kim et al. GENOME RESEARCH
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation